Does Medicaid Cover GLP-1 in Ohio? Diabetes, MASH, and Prior Auth

Ohio Medicaid does cover GLP-1 medications, but only for specific medical diagnoses. The program pays for drugs like Ozempic and Mounjaro when they’re prescribed for Type 2 diabetes, and starting April 1, 2026, it covers Wegovy for two additional uses: reducing cardiovascular risk in certain high-risk patients and treating a liver condition called MASH. Ohio Medicaid does not cover any GLP-1 prescribed for weight loss alone, and in most cases a prescriber must submit a prior authorization request before the pharmacy can fill it.¹

Coverage for Type 2 Diabetes

If you have a documented Type 2 diabetes diagnosis, several GLP-1s sit on Ohio Medicaid’s preferred drug list. The current preferred agents are Byetta (exenatide), Trulicity (dulaglutide), and Victoza (liraglutide). These usually don’t need extra prior authorization beyond the diabetes diagnosis itself.¹

Ozempic and Mounjaro are handled differently. Since September 2024, both require prior authorization from the prescribing provider if there isn’t already an active authorization on file. Requests are reviewed against the clinical criteria on Ohio’s Unified Preferred Drug List, which standardizes pharmacy coverage across every managed care plan (Molina, CareSource, UnitedHealthcare, and others) and fee-for-service Medicaid.²

One recent change worth flagging: as of December 8, 2025, every pharmacy claim for a preferred GLP-1 must include a documented Type 2 diabetes diagnosis, either in the member’s medical record or submitted directly on the pharmacy claim. Missing documentation is a common reason claims get rejected at the counter.¹

Weight Loss Is Not Covered

Ohio Medicaid’s pharmacy benefit explicitly excludes GLP-1s prescribed for weight loss or prediabetes. The pharmacy benefit manager site states that “for all other non-FDA approved uses (such as prediabetes or weight loss), coverage will not be available,” and the official member handbook confirms that the program does not cover “drugs for the treatment of obesity.”³

In practical terms, that means Wegovy and Zepbound (the brand-name formulations approved for obesity) are not covered when prescribed for that purpose. The same active ingredients packaged for diabetes, semaglutide as Ozempic and tirzepatide as Mounjaro, can be covered when prescribed and authorized for Type 2 diabetes.

This exclusion is allowed under federal law. The Medicaid Drug Rebate Program generally requires states to cover nearly all FDA-approved drugs from participating manufacturers, but a specific carve-out in 42 U.S.C. § 1396r-8 lets states exclude drugs “used for anorexia, weight loss, or weight gain.” Ohio uses that option.⁴

New Coverage for Cardiovascular Risk and MASH

Effective April 1, 2026, Ohio Medicaid added narrow coverage for Wegovy under two non-obesity indications. The state’s Pharmacy and Therapeutics Committee created a new drug category called “Metabolic Modifiers” and approved Wegovy as the preferred agent for reducing the risk of major adverse cardiovascular events (MACE) and for treating metabolic dysfunction-associated steatohepatitis (MASH).⁵

Both indications require clinical prior authorization, and the eligibility criteria are strict.

For MACE risk reduction, the patient must be 18 or older, have a BMI of at least 27, and must not have Type 1 or Type 2 diabetes (A1C below 6.5%). The patient must have a documented history of a prior heart attack, stroke, or symptomatic peripheral artery disease, and must already be on standard cardiovascular therapy including an antiplatelet agent, a lipid-lowering drug, and blood pressure medication.⁵

For MASH, the patient must be 18 or older with documented noncirrhotic MASH and moderate to advanced liver fibrosis (stage F2 or F3), confirmed by a liver biopsy within the past 24 months or by two qualifying diagnostic tests. The patient must also be following a reduced-calorie diet and exercise plan and have optimized treatment for related conditions like coronary artery disease and high cholesterol.⁶

Each authorization lasts 180 days. To renew, the patient must show at least 5% weight loss from baseline and 80% medication adherence. For MASH, the patient must also show measurable improvement in liver inflammation or fibrosis.⁵

How Prior Authorization Works

All Ohio Medicaid pharmacy prior authorizations go through Gainwell, the state’s single pharmacy benefit manager. Your prescriber submits the request. They can do that electronically through the Agadia PromptPA Portal, by fax at 833-679-5491, or by phone at 833-491-0344. Prior authorization forms live on the SPBM portal, and requests are processed within 24 hours.¹

If the pharmacy tells you a GLP-1 isn’t covered, the first step is usually to confirm your prescriber has submitted a prior authorization with the right diagnosis documentation attached. Most initial denials turn on paperwork rather than clinical disagreement.

If Your Request Is Denied

You have 60 calendar days from the date on the denial letter to file an appeal with Gainwell. You can appeal:

By phone at 1-833-491-0344, option 1
By email to OH_MCD_PBM@gainwelltechnologies.com
Through the SPBM member portal
By mail to Gainwell Pharmacy Services

Include your name, Medicaid ID, your prescriber’s name, and an explanation of why you disagree with the denial. Gainwell has 15 calendar days to respond. An expedited review is available if waiting would jeopardize your health.⁷

If the appeal is also denied, you can request a state hearing within 90 calendar days of the appeal decision. State hearing requests go through the Ohio Department of Job and Family Services, online, by phone at 1-866-635-3748, or by email to bsh@jfs.ohio.gov.⁷

What Could Change

Two federal developments could eventually widen Ohio’s coverage. The Trump administration launched the BALANCE model (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) in December 2025, a voluntary five-year demonstration run through the CMS Innovation Center under which manufacturers negotiate lower GLP-1 prices for participating state Medicaid programs and Medicare. Medicaid coverage expansion under the model began May 1, 2026, with a state application deadline of July 31, 2026. Whether Ohio will participate has not been announced.⁸

CMS has also proposed a rule (CMS-4208-P) that would require state Medicaid programs to cover anti-obesity medications, overriding the federal exception Ohio currently uses. The National Association of Medicaid Directors has argued the proposed 60-day implementation timeline is unrealistic and estimated annual costs of $30 million to $126 million per state.⁹ Congress has reintroduced the Treat and Reduce Obesity Act in both chambers of the 119th Congress, which would remove the Medicaid weight-loss drug exclusion if enacted.¹⁰ Neither the rule nor the legislation has been finalized, and no pending Ohio bill would expand Medicaid coverage of GLP-1s for obesity.

Until something changes at the federal level or in Columbus, the rule for Ohio Medicaid remains straightforward: a qualifying diagnosis gets you a GLP-1; a weight-loss prescription alone does not.

1
Ohio Medicaid SPBM Portal. Ohio Medicaid Single Pharmacy Benefit Manager
2
Ohio Department of Medicaid. Unified Preferred Drug List
3
Ohio Medicaid. SPBM Member Handbook
4
KFF. Medicaid Coverage of and Spending on GLP-1s
5
Ohio Department of Medicaid. 30-Day Change Notice, Effective April 1, 2026
6
Ohio Department of Medicaid. Pharmacy and Therapeutics Committee Meeting Minutes, January 7, 2026
7
Ohio Medicaid. Member Pharmacy FAQs
8
KFF. What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid
9
National Association of Medicaid Directors. Optional, Not Mandatory: NAMDs Recommendations on Anti-Obesity Medication Coverage
10
U.S. Congress. H.R. 4231, Treat and Reduce Obesity Act of 2025